SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. CTMX, a leader in conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the US market close. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

Attendees can access the live webcast of the conference call through the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants can register for the conference call Here and it is recommended to do this at least 10 minutes before joining the call. An archived replay of the webcast will be available on the company’s website.

About CytomX Therapeutics, Inc.
CytomX is an oncology-focused, clinical-stage biopharmaceutical company dedicated to the differential destruction of cancer. CytomX aims to push the boundaries of current cancer treatments by developing a novel class of conditionally activated biologics based on the Probody® technology platform. CytomX’s robust and differentiated pipeline includes five therapeutic candidates across multiple treatment modalities, including antibody-drug conjugates (“ADCs”), T-cell-binding bispecific antibodies (“TCBs”), and immunomodulators such as cytokines and checkpoint inhibitors (“CPIs “). . CX-2029 is an investigational conditionally activated antibody-drug conjugate (ADC) targeting CD71 that is being developed in collaboration with AbbVie. CytomX’s clinical pipeline also includes anti-cancer immunotherapeutic candidates against validated targets such as CTLA-4-targeted probody therapeutic BMS-986288, developed in partnership with Bristol Myers Squibb, and CX-904, a conditionally activated bispecific antibody that on T cells, epidermal growth factor receptor (EGFR) attacks on tumor cells and the CD3 receptor on T cells partnered with Amgen. Additionally,…